FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2746062983> ?p ?o ?g. }

• W2746062983 endingPage "84257" @default.
• W2746062983 startingPage "84248" @default.
• W2746062983 abstract "Zoledronic acid (ZOL) has been used as an adjuvant therapy for breast cancer. It is suggested that ZOL might be associated with inhibition of macrophages, which in turn reduces tumor growth, metastasis and tumor angiogenesis. Moreover, metronomic therapy can inhibit tumor angiogenesis and tumor immune cells. Previously we developed ZOL based cationic liposomes that allowed a higher intratumor delivery of drug compared with free ZOL in vivo. Therefore, in this study, Asn-Gly-Arg (NGR) and PEG2000 were used as ligands to modify the surface of liposomes (NGR-PEG-LP-ZOL) in metronomic therapy to clear the tumor-associated macrophages (TAMs) and inhibit the formation of tumor angiogenesis, achieving the purpose of anti-tumor growth. Our data showed that NGR-PEG-LP-ZOL metronomic therapy has the strongest inhibitory effect on tumor growth. Further, NGR-PEG-LP-ZOL metronomic therapy could significantly impair TAMs by inhibiting the expression of CD206 antibody in tumor tissues, decreasing the expression of cytokine related gene expression of TAMs, as well as reducing the percentage of TAMs in tumor tissues. In addition, NGR-PEG-LP-ZOL metronomic therapy could significantly inhibit the expression of tumor neovascular specific antibody CD31 and reduce the microvessel density. In conclusion, our study demonstrated that NGR-PEG-LP-ZOL metronomic therapy could impair TAMs by inhibiting tumor angiogenesis and enhance the antitumor effect of ZOL." @default.
• W2746062983 created "2017-08-31" @default.
• W2746062983 creator A5018093835 @default.
• W2746062983 creator A5051247287 @default.
• W2746062983 creator A5057922659 @default.
• W2746062983 creator A5061799232 @default.
• W2746062983 creator A5062477934 @default.
• W2746062983 creator A5065297872 @default.
• W2746062983 creator A5068139112 @default.
• W2746062983 creator A5081643835 @default.
• W2746062983 creator A5085025467 @default.
• W2746062983 date "2017-08-24" @default.
• W2746062983 modified "2023-10-02" @default.
• W2746062983 title "Anti-angiogenic and anti-tumor effects of metronomic use of novel liposomal zoledronic acid depletes tumor-associated macrophages in triple negative breast cancer" @default.
• W2746062983 cites W1861588860 @default.
• W2746062983 cites W1973091654 @default.
• W2746062983 cites W1981315061 @default.
• W2746062983 cites W1982855449 @default.
• W2746062983 cites W1996523699 @default.
• W2746062983 cites W2004152105 @default.
• W2746062983 cites W2020445584 @default.
• W2746062983 cites W2021070226 @default.
• W2746062983 cites W2029883816 @default.
• W2746062983 cites W2047902191 @default.
• W2746062983 cites W2059409197 @default.
• W2746062983 cites W2063680739 @default.
• W2746062983 cites W2063992586 @default.
• W2746062983 cites W2066204710 @default.
• W2746062983 cites W2074470232 @default.
• W2746062983 cites W2105513551 @default.
• W2746062983 cites W2113581209 @default.
• W2746062983 cites W2139774670 @default.
• W2746062983 cites W2144309103 @default.
• W2746062983 cites W2146990673 @default.
• W2746062983 cites W2154097649 @default.
• W2746062983 cites W2155343550 @default.
• W2746062983 cites W2155820414 @default.
• W2746062983 cites W2158997529 @default.
• W2746062983 cites W2168669893 @default.
• W2746062983 cites W2178075163 @default.
• W2746062983 cites W2184642485 @default.
• W2746062983 cites W2296591928 @default.
• W2746062983 cites W2316348835 @default.
• W2746062983 cites W2338768170 @default.
• W2746062983 cites W2341580698 @default.
• W2746062983 cites W2341824147 @default.
• W2746062983 cites W2346326630 @default.
• W2746062983 cites W2472309196 @default.
• W2746062983 cites W2541478996 @default.
• W2746062983 cites W2544538967 @default.
• W2746062983 cites W2560411154 @default.
• W2746062983 cites W2575489745 @default.
• W2746062983 cites W4241664300 @default.
• W2746062983 doi "https://doi.org/10.18632/oncotarget.20539" @default.
• W2746062983 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5663592" @default.
• W2746062983 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29137420" @default.
• W2746062983 hasPublicationYear "2017" @default.
• W2746062983 type Work @default.
• W2746062983 sameAs 2746062983 @default.
• W2746062983 citedByCount "17" @default.
• W2746062983 countsByYear W27460629832019 @default.
• W2746062983 countsByYear W27460629832020 @default.
• W2746062983 countsByYear W27460629832021 @default.
• W2746062983 countsByYear W27460629832022 @default.
• W2746062983 countsByYear W27460629832023 @default.
• W2746062983 crossrefType "journal-article" @default.
• W2746062983 hasAuthorship W2746062983A5018093835 @default.
• W2746062983 hasAuthorship W2746062983A5051247287 @default.
• W2746062983 hasAuthorship W2746062983A5057922659 @default.
• W2746062983 hasAuthorship W2746062983A5061799232 @default.
• W2746062983 hasAuthorship W2746062983A5062477934 @default.
• W2746062983 hasAuthorship W2746062983A5065297872 @default.
• W2746062983 hasAuthorship W2746062983A5068139112 @default.
• W2746062983 hasAuthorship W2746062983A5081643835 @default.
• W2746062983 hasAuthorship W2746062983A5085025467 @default.
• W2746062983 hasBestOaLocation W27460629831 @default.
• W2746062983 hasConcept C121608353 @default.
• W2746062983 hasConcept C126322002 @default.
• W2746062983 hasConcept C150903083 @default.
• W2746062983 hasConcept C155887181 @default.
• W2746062983 hasConcept C207001950 @default.
• W2746062983 hasConcept C2776326535 @default.
• W2746062983 hasConcept C2779013556 @default.
• W2746062983 hasConcept C2780394083 @default.
• W2746062983 hasConcept C502942594 @default.
• W2746062983 hasConcept C54009773 @default.
• W2746062983 hasConcept C54355233 @default.
• W2746062983 hasConcept C71924100 @default.
• W2746062983 hasConcept C81885089 @default.
• W2746062983 hasConcept C86803240 @default.
• W2746062983 hasConcept C98274493 @default.
• W2746062983 hasConceptScore W2746062983C121608353 @default.
• W2746062983 hasConceptScore W2746062983C126322002 @default.
• W2746062983 hasConceptScore W2746062983C150903083 @default.
• W2746062983 hasConceptScore W2746062983C155887181 @default.
• W2746062983 hasConceptScore W2746062983C207001950 @default.
• W2746062983 hasConceptScore W2746062983C2776326535 @default.
• W2746062983 hasConceptScore W2746062983C2779013556 @default.

• next